IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma

Siti Muhamad Nur Husna¹, Norasnieda Md Shukri², Noor Suryani Mohd Ashari¹ and Kah Keng Wong¹

¹ Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia
² Department of Otorhinolaryngology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia

ABSTRACT

Allergic rhinitis (AR) is a common disorder of the upper airway, while asthma is a disease affecting the lower airway and both diseases are usually comorbid. Interleukin (IL)-4 and IL-13 are critical cytokines in the induction of the pathogenic Th2 responses in AR and asthma. Targeting the IL-4/IL-13 axis at various levels of its signaling pathway has emerged as promising targeted therapy in both AR and asthma patient populations. In this review, we discuss the biological characteristics of IL-4 and IL-13, their signaling pathways, and therapeutic antibodies against each cytokine as well as their receptors. In particular, the pleiotropic roles of IL-4 and IL-13 in orchestrating Th2 responses in AR and asthma patients indicate that dual IL-4/IL-13 blockade is a promising therapeutic strategy for both diseases.

INTRODUCTION

Allergic rhinitis (AR) is an upper airway disorder due to contact of nasal mucosa with allergens that trigger IgE-mediated inflammation, leading to symptoms such as sneezing, coughing, nasal congestion and rhinorrhea. Asthma, on the other hand, is a lower airway disorder caused by various triggers such as allergies, smoking, air pollution or sinusitis, resulting in airway muscles spasms and inflammation, airway obstruction, wheezing and dyspnea (Azid et al., 2019; Eguiluz-Gracia et al., 2020; Meng, Wang & Zhang, 2020; Nur Husna et al. 2022a; Nur Husna et al. 2021b; Sani et al., 2019). AR and asthma prevalence worldwide has seen a rapid increase where approximately 40% and 334 million people worldwide have been affected with AR and asthma, respectively (Bousquet et al., 2008; Network GAJA, New Zealand, 2014). Asthma is a fatal disease and accountable for 250,000 possibly preventable deaths annually (Enilari & Sinha, 2019). Both AR and asthma usually comorbid with each other in the same individual or in closely related family members, partly due to shared genetic risk variants of immune-related genes in these diseases (Belsky et al., 2013; Ferreira et al., 2017; Ober & Yao, 2011; Van Beijsterveldt & Boomsma, 2007). AR is believed to be a risk factor for asthma, with over 80% of asthmatic patients have rhinitis and 10–40% of AR patients have asthma (Bousquet et al., 2008; Bousquet et al., 2001).
“united airway disease hypothesis” proposes that both upper and lower airway diseases are manifestations of an inflammatory process (Togias, 2003).

Both diseases are mediated by T helper 2 (Th2) inflammatory processes where Th2 cytokines such as IL-4, IL-5 and IL-13 play key roles in their pathogenesis (Nur Husna et al. 2022c). IL-4 plays key roles in inducing IgE production by plasma cells and upregulating the expression of FceRI and MHC class II molecules in mast cells, basophils, monocytes, macrophages and B cells (Yamanishi et al., 2017; Yip et al., 2021). IL-4 is considered a master Th2 switch that also drives the generation of other pro-allergic cytokines such as IL-5 and IL-13 by Th2 cells in allergic diseases. IL-4 promotes the development of myeloid dendritic cells (mDCs) and involved in the migration of Th2 cells and eosinophils to the inflamed site. Both IL-4 and IL-13 activate B cells to synthesize IgE, induce goblet cell hyperplasia, trigger airway hyperresponsiveness and mucus hypersecretion (Sahoo, Wali & Nurieva, 2016; Wills-Karp & Finkelman, 2008). Moreover, Th2 cytokines also reduce the integrity of nasal epithelial barrier in AR and asthma patients by reducing the expression of tight junction (TJ) proteins in epithelial cells (Heijink, Nawijn & Hackett, 2014; Holgate, 2007; Steelant et al., 2016b; Steelant et al., 2018).

Our understanding of the pathophysiology of AR has progressed rapidly over the last few decades whereby AR and asthma are exacerbated by aberrantly high cytokines levels (Gandhi, Pirozzi & Graham, 2017; May & Fung, 2015; Nur Husna et al. 2022b; Yu et al., 2019) and the disruption of airway epithelial barrier (Nur Husna et al. 2021a; Steelant et al., 2016a; Steelant et al., 2018). However, long-term effective treatments for these diseases are still unmet with rising cases over the years. IL-4/IL-13 axis is important in the pathogenesis of AR and asthma in which the axis exerts a wide range of effects on inflammatory cells and structural changes to airway epithelial cells in AR and asthma. A proportion of chronic AR and asthma patients do not respond towards conventional, symptoms-based medications. These patients require disease-modifying therapeutic agents such as targeted agents against IL-4/IL-13 that can shift the natural course of disease progression in AR and asthma (Nur Husna et al. 2022c). Accumulating evidence from ex vivo studies as well as AR or asthma animal models lend credence to the further assessment of IL-4/IL-13-targeted therapy in AR and asthma patients (Bourdin et al., 2021; Conde et al., 2021; Harb & Chatila, 2020; Russkamp et al., 2019).

Therefore, in this review, the IL-4/IL-13 signaling pathways and therapeutic monoclonal antibodies targeting each cytokine or their receptors, as well as dual IL-4/IL-13 blockade, in both AR and asthma are presented and discussed. The review summarises the key biological and therapeutic features of this vital signaling axis in the two major upper airway disorders that would be informative for otorhinolaryngology clinicians and researchers alike in this field.

**SURVEY METHODOLOGY**

This review is pertaining to IL-4/IL-13 axis and their receptors i.e., IL-4Rα, IL-13Rα1 and IL-13Rα2 in AR and asthma research. All articles were searched, retrieved and screened by an investigator (SMNH) and independently verified by another investigator (KKW).
according to the electronic databases Google Scholar and PubMed. Only English language articles were included and articles up to year 2021 were shortlisted. The keywords used were as follows: “allergic rhinitis”, “asthma”, “AR”, “IL-4”, “IL-13”, “IL-4/IL-13”, “IL-4/IL-13 axis”, “IL-4Rα”, “IL-13Rα1”, “IL-13Rα2”, “monoclonal antibodies” and “therapeutic antibodies”.

**Biological characteristics of IL-4 and IL-13 receptor complexes**

The genes encoding IL-4 and IL-13 are located in chromosome 5q31 where this genetic loci is home to a cluster of cytokine genes such as IL-3, IL-4, IL-5, IL-13 and granulocyte-macrophage colony stimulating factor (Giuffrida et al., 2019). IL-4 is produced by T cells, basophils and mast cells where it induces differentiation of T cells into Th2 subtype (Ptackova et al., 2018). IL-13 is produced by several immune cell populations including Th2 cells, mast cells, B cells, NK cells, innate lymphoid cells and granulocytes (Giuffrida et al., 2019; Joshi et al., 2006). IL-4 signaling pathway initiates immunoglobulin class switching toward IgE in B cells (Paul, 2015), while IL-13 triggers changes in epithelial and smooth muscle cell functions leading to hypersensitivity reactions (Ito et al., 2009; Wills-Karp & Finkelman, 2008).

IL-4 and IL-13 are structurally similar, multifunctional peptides and share a functional signaling receptor chain. IL-4 binds to two receptors i.e., the type I IL-4 receptor (IL-4R) composed of IL-4Rα and common γ-chain (γc), and type II IL-4R composed of IL-4Rα and IL-13Rα1. IL-4Rα is present on various types of cells including CD4+ and CD8+ T cells, lung epithelial cells, B cells, macrophages, airway goblet cells, and smooth muscle cells (Tan, Sugita & Akdis, 2016). On the other hand, IL-13R α1 is expressed by B cells, eosinophils, macrophages, lung epithelial cells, airway goblet cells, and endothelial cells (Tan, Sugita & Akdis, 2016).

The type I IL-4R complex is found on the surface of lymphoid T and NK cells, basophils, mast cells and most mouse B cells, while type II IL-4R is present on the surface of non-lymphoid and tumor cells (Koller et al., 2010; Wills-Karp & Finkelman, 2008). Another receptor that binds IL-13 only is IL-13Rα2 where it acts as a decoy receptor, and usually overexpressed as well as activated in tumor cells or fibrosis (Bartolome, Jaen & Casal, 2018; Fichtner-Feigl et al., 2006).

**IL-4 and IL-13 activate the IL-4Rα/STAT6 pathway to induce allergic responses**

Allergic response is triggered when DCs present allergen peptides to CD4+ T cells that then differentiate into Th2 cells to produce Th2 cytokines. Binding of IL-4 with its type I receptor which comprises of IL-4Rα and γc chain leads to activation of JAK1 and JAK3, respectively. For type II IL-4R, binding of IL-13 with IL-13Rα1 subunit activates TYK2/JAK2 (Nguyen et al., 2020; Wang et al., 2020). Activated JAKs facilitate tyrosine residues phosphorylation of the cytoplasmic tail of IL-4R. Following JAK3 activation, inflammatory mediators (e.g., histamines, leukotrienes) and cytokines (e.g., IL-4, IL-13 and IL-9) are released which influence the responses of neighboring cells (i.e B cells, mast cells, macrophages, dendritic cells and endothelial cells), triggering IgE production by
plasma cells, eosinophils infiltration, airway inflammation, bronchoconstriction and tissue damage (Malaviya, Laskin & Malaviya, 2010).

The phosphorylated tyrosine residues serve as docking sites for STAT6 (a transcription factor selectively coupled to the IL-4Rα chain), activating IL-4 and IL-13 responsive genes in the subsequent signaling pathway of allergic responses. STAT6 induces Sonic hedgehog expression in the airway epithelium leading to goblet cell metaplasia and enhanced mucus production in asthma. pSTAT6 is associated with the production of Th9 cells and IL-9 during airway inflammation (Hoppenot et al., 2015). Activated macrophage marker Arginase 1 (Arg-1) can be induced by IL-4 and IL-13 which ultimately increase the production of L-ornithine and its downstream products polyamines and L-proline (i.e., inflammatory mediators causing airway remodeling) (Van Den Berg, Meurs & Gosens, 2018). Arg-1 inhibitors were recently patented for the treatment of AR and asthma (Meurs et al., 2019).

This activates B cells to produce circulating IgE that binds to specific Fcε receptors on mast cells and basophils. Signaling activation from Th2-type cytokines are important survival signals for mast cells, basophils, and eosinophils. Degranulation of mast cells results in the release of inflammatory mediators such as histamine, tryptase, chymase, kininogenase (generates bradykinin), heparin, prostaglandin D2 and the sulfidopeptidyl leukotrienes (Skoner, 2001). In AR, these mediators induce mucosal edema and watery rhinorrhea, while histamine activates its H1 receptors on sensory nerve endings that causes sneezing, pruritus, and reflex secretory responses. Moreover, histamine-mediated activation of H1 and H2 receptors on mucosal blood vessels leads to nasal congestion and plasma leakage (Sin & Togias, 2011). During the late phase in AR, nasal mucosal inflammation occurs with the influx and activation of a variety of inflammatory cells (i.e., T cells, eosinophils, basophils, neutrophils, and monocytes) into nasal mucosa that depends on Th2 cytokines e.g., IL-4, IL-5 and IL-13 (Sin & Togias, 2011). In asthma, the provocative discharges can spread from the upper airway to lungs, which triggers inflammation and bronchoconstriction (Stone, Prussin & Metcalfe, 2010). Airway hyperresponsiveness is a hallmark feature of asthma due to exaggerated bronchoconstrictor response (Sinyor & Perez, 2020).

Furthermore, IL-4 and IL-13 are not only responsible for initiating inflammatory responses, but they also play important roles in disrupting nasal epithelial barrier integrity. The cytokines may accumulate within the sinonasal microenvironment surrounding sinonasal epithelial cells, activating IL-4/IL-13 axis signaling cascade that impairs epithelial TJ composition (Capaldo & Nusrat, 2009; London Jr, Tharakan & Ramanathan Jr, 2016). The signaling cascade deregulates the expression and assembly of epithelial TJ molecules, leading to increased nasal epithelial permeability to allergens (Capaldo & Nusrat, 2009; Steelant et al., 2018). The cytokines also obstruct the epithelial barrier from resealing which preserves the contact with inflammatory allergens (London Jr, Tharakan & Ramanathan Jr, 2016).

Association of IL-4/IL-13 axis with impaired nasal epithelial barrier integrity has been observed in both AR and asthma patients. In AR patients, treatment with anti-IL-4Rα monoclonal antibodies (mAbs) successfully restored epithelial barrier integrity and function (Steelant et al., 2018). IL-4 could disrupt epithelial integrity of primary nasal
epithelial cells by reducing TJ molecules expression including zonula occludens-1 (ZO1) and occludin (OCLN) (Steelant et al., 2016a). Reduced expression of these TJ molecules in nasal epithelial cells are frequently observed in AR patients (Nur Husna et al., 2021a; Siti Sarah et al., 2020; Steelant et al., 2016a; Wang Ms et al., 2021). Addition of IL-4 and IL-13 to reconstructed human epidermis (RHE) cells resulted in downregulation of CLDN1 expression in AR (Gruber et al., 2015).

The IL-4/IL-13 axis also plays important roles in the pathophysiology of inflammatory arthritis especially rheumatoid arthritis (RA). In RA, IL-4/IL-13 cytokines promote the production of proinflammatory cytokines such as IL-1β and TNF-α, as well as macrophage polarization from classically activated (M1) phenotype into the alternatively activated (M2) phenotype (Iwaszko, Biały & Bogunia-Kubik, 2021). These collectively promote inflammation of the joints in RA patients. On the other hand, in AR patients, IL-4/IL-13 axis primarily induces the recruitment of mDCs, eosinophils and overproduction of IgE by plasma cells, as well as repressing the expression of TJs by nasal epithelial cells. The pathophysiological differences of IL-4/IL-13 axis in RA and AR patients are likely due to distinct causative factors in both diseases whereby in AR, allergens are the key trigger while RA is multifactorial (i.e., hormones, genetics and environmental factors), leading to dissimilar clinical manifestations.

IL-4/IL-13 axis is a promising therapeutic target in AR and asthma. Development of novel therapies targeting IL-4/IL-13 axis can be achieved by disrupting its signaling axis at various molecular levels such as inhibition of the soluble cytokines and their receptors on cell surfaces. Several therapeutic mAbs targeting IL-4 and IL-13 and their receptors have been developed to date and are discussed in the next sections.

**Therapeutic antibodies targeting IL-4/IL-13 axis in AR**

**Anti-IL-4 mAb in AR**

VAK694 is a fully humanized anti-IL-4 mAb that has been assessed in AR patients. A phase IIa randomized controlled trial (RCT) of VAK694 in AR patients to examine its efficacy had been conducted (Chaker et al., 2016). The VAK694 dosage (3 mg/kg every 4 weeks) used was based on previous phase I studies (NCT00620230 and NCT00929968). In this study, seasonal AR patients (n = 37) were randomized into three groups i.e., combination of subcutaneous allergen immunotherapy (SCIT) with VAK694, suboptimal SCIT with placebo antibody, and double placebo (placebo SCIT and placebo antibody) and the primary endpoint assessed was suppression of skin late-phase response (LPR). However, no significant difference in the skin LPR in the VAK694 plus SCIT group compared with the SCIT-only group. The authors concluded that anti–IL-4 treatment with VAK694 was effective in modulating Th2 memory when applied during administration of specific immunotherapy, but it did not provide additional clinical efficacy. It was further suggested that upcoming clinical studies to include combined intervention with allergen, allergen dose, and biological agents.

**Anti-IL-13 mAb in AR**

Dectrekumab (also known as QAX-576) is a fully human investigational anti-IL-13 mAb with anti-inflammatory potential. It is widely investigated in immune disorders including
AR asthma, eosinophilic esophagitis (EoE), Crohn’s disease and keloids (Rothenberg et al., 2015). A phase II double-blind study on dectrekumab (QAX576) aimed to evaluate the effects of the anti–IL-13 mAb \( n = 16 \) compared with placebo \( n = 15 \) on repeated nasal allergen challenge responses in AR patients out of season (Kariyawasam et al., 2009; Nicholson et al., 2011).

A significant decrease in IL-13 levels was observed in patients administered with anti–IL-13 mAb compared with the placebo group after nasal allergen challenge on day 5 and day 7. However, there were no obvious effects of dectrekumab on nasal lavage eosinophil numbers or total nasal symptom scores compared to placebo. Dectrekumab treatment only managed to decrease total nasal symptom scores in a subgroup with high late-phase nasal IL-13 levels. The antibody inhibited nasal IL-13 responses but failed to inhibit nasal symptoms and eosinophils, suggesting that anti-IL-13 is not critical for acute nasal allergic response (Kariyawasam et al., 2009).

Therapeutic antibodies targeting IL-4/IL-13 axis in asthma

Anti-IL-4 mAb in Asthma

Pascolizumab (SB 240683) is a humanized mAb against IL-4. A preclinical study was first conducted to generate pascolizumab as a murine mAb (3B9) with specificity for human IL-4, which was subsequently humanized (Hart et al., 2002). It was tested in cynomolgus monkeys where they received monthly intravenous doses (up to 100 mg per kg) for 9 months, and pascolizumab was reported to be well-tolerated (Hart et al., 2002). The dose-escalation phase I RCT of pascolizumab was assessed in mild-to-moderate asthma adult patients. Pascolizumab was well-tolerated at single intravenous doses of 0.5–10 mg/kg with an elimination half-life of more than 2 weeks (Shames et al., 2001). A multidose phase I/II trial of pascolizumab in symptomatic steroid-naïve subjects with asthma \( n = 120 \) was conducted, however it was terminated because preliminary data showed that pascolizumab did not provide clinical benefit (NCT00024544).

Anti-IL-13 mAb in Asthma

Numerous experimental studies have shown that IL-13 as a potential therapeutic target in asthma. In mouse models of asthma, intravenous IL-13-targeted mAb administration effectively inhibited allergen-induced inflammation, goblet cell hyperplasia and airway remodelling (Yang et al., 2004). Lebrikizumab, a humanized anti–IL-13 mAb, was produced to potentially treat asthma patients with “Th2-high” asthmatic phenotypes characterized by overexpression of IL-13-inducible genes such as the gene encoding periostin (an extracellular matrix protein produced by bronchial epithelial cells) (Woodruff et al., 2009). Periostin plays pathogenic roles in asthma patients where it induces mucus secretion, airway fibrosis and tissue remodelling (O’Dwyer & Moore, 2017).

In a randomized multicenter study (Corren et al., 2011) of moderate-to-severe asthmatic adult patients \( n = 219 \) whose disease was inadequately controlled by inhaled corticosteroid therapy, lebrikizumab was administered at monthly subcutaneous doses of 250 mg for 6 months. Lebrikizumab elicited improved lung function in these patients who demonstrated high serum levels of periostin. At week 12, the forced expiratory volume in the first second (FEV1) increased compared with baseline values for lebrikizumab-treated group, and
this was more pronounced in the high-periostin than low-periostin subgroup of patients. In the LUTE ($n = 258$) and VERSE ($n = 205$) replicated phase IIb RCTs, the efficacy of lebrikizumab as anti-IL-13 mAb was assessed in moderate-to-severe asthma patients (Hanania et al., 2015). Treatment with lebrikizumab resulted in 60% reduction in the rate of asthma exacerbations, which was more noticeable in the periostin-high patients compared with the periostin-low patients. Improvement in FEV1 was also higher in periostin-high patients compared with periostin-low patients. Collectively, these studies demonstrated the significant efficacy of lebrikizumab in periostin-high patients.

In phase III trials of LAVOLTA I ($n = 1,081$) and LAVOLTA II ($n = 1,067$), the efficacy and safety of lebrikizumab in adult patients with uncontrolled asthma, despite inhaled corticosteroids and at least one-second controller medication, was assessed (Hanania et al., 2016). Patients were randomly assigned to receive lebrikizumab or placebo subcutaneously, once every 4 weeks. It was shown that the exacerbation rates were reduced in biomarker-high patients (periostin $\geq 50$ ng/mL or blood eosinophils $\geq 300$ cells per $\mu$L) treated with lebrikizumab versus placebo in both trials. Lebrikizumab successfully blocked IL-13, however it did not consistently show significant reduction in asthma exacerbations in biomarker-high patients.

Tralokinumab is a fully human IgG4 mAb that employs a distinct mode of action from lebrikizumab where it binds to IL-13 cytokine at an epitope that overlaps with the binding site of the IL-13R$\alpha$ receptors, preventing IL-13 from binding to both IL-13R$\alpha$1 and IL-13R$\alpha$2 (Popovic et al., 2017). Interestingly, this strategy is proposed to be more efficacious than blocking the binding to IL-13R$\alpha$1 alone (Tripp et al., 2017). Preclinical studies of tralokinumab in mice model of respiratory and esophageal inflammation induced by intratracheal human IL-13 showed that the mAb markedly attenuated airway eosinophilia and bronchial hyperresponsiveness (Blanchard et al., 2005). In the two phase I clinical trials of tralokinumab, this antibody demonstrated an acceptable safety profile in asthmatic patients ($n = 23$) (Singh et al., 2010) and administration of 300 mg tralokinumab was well tolerated in asthma patients ($n = 20$) in another trial (Baverel et al., 2015).

Phase II trial was conducted in moderate-to-severe uncontrolled asthma ($n = 194$) resulted in improved lung function (FEV1) compared to placebo, however no changes in Asthma Control Questionnaire score (ACQ) was observed (Piper et al., 2013). A non-significant reduction in asthma exacerbation rates was observed in severe uncontrolled asthma patients ($n = 150$) in a separate phase IIb trial (Brightling et al., 2015). Additionally, eosinophil count in bronchial biopsy was assessed in phase II trial (MESOS) of inadequately controlled moderate-to-severe asthma patients ($n = 39$) versus placebo demonstrated insignificant changes in bronchial eosinophil count, however tralokinumab reduced fractional exhaled nitric oxide (FeNO) and total blood IgE concentrations in the patients (Russell et al., 2018).

In two phase III trials, STRATOS 1 (all-comers population, $n = 398$) and STRATOS 2 (FeNO-high population, $n = 108$), both trials was assessed in severe, uncontrolled asthma patients (Panettieri Jr et al., 2018). In the STRATOS 1 study, tralokinumab reduced asthma exacerbation rate in severe asthma patients (FeNO $\geq 37$ ppb), but the reduction was insignificant in the STRATOS 2 study. These inconsistent results suggested that IL-13
signaling pathway may not play causative roles of severe asthma exacerbation. Lastly, phase III trial (TROPOS) of tralokinumab in severe, uncontrolled asthma patients \( (n = 140) \) aimed to reduce the dependency of oral corticosteroid (OCS) use. However, no significant changes were observed in the final daily average OCS dose compared to placebo \((Busse et al., 2019)\). Taken together, tralokinumab administration has not yielded clinical benefits in controlling asthma.

**Dupilumab as a dual IL-4/IL-13 blockade antibody in AR and asthma**

The recent failure of the IL-13 inhibitor tralokinumab to show efficacy in phase III trials of asthma patients underscores the need for other more effective IL-4/IL-13 inhibitors. Dupixent (dupilumab) is a fully human mAb \((Macdonald et al., 2014)\). It is a first-in-class biologic that binds to both monomeric and dimeric human IL-4R\(\alpha\) (type I and type II receptors), with \(K_D\) values of 33 pM and 12 pM, respectively, preventing both IL-4- and IL-13-mediated signaling pathways. The antibody has demonstrated clinical benefits for patients with type 2 signature diseases, leading to its approval for the treatment of asthma, chronic sinusitis patients with nasal polyps, and moderate-to-severe atopic dermatitis \((Beck et al., 2014; Blauvelt et al., 2017; Hamilton et al., 2014; Le Floch et al., 2020; Rabe et al., 2018; Simpson et al., 2016; Thaci et al., 2016; Wenzel et al., 2013)\).

In preclinical investigation utilizing primary cell assays and murine model of house dust mite (HDM)–induced asthma, the efficacy of IL-4 vs IL-13 vs IL-4R\(\alpha\) blockers was assessed \((Le Floch et al., 2020)\). Dupilumab was responsible to reduce thymus and activation-regulated chemokine (TARC) and IgE levels \((i.e., two effector molecules implicated in type 2 diseases)\), and fully blocked CD23 upregulation on B cells and IL-12p70 secretion from monocyte-derived DCs \((Le Floch et al., 2020)\). Dupilumab also suppressed the infiltration of pathogenic cells such as ST2\(^{+}\)CD4\(^{+}\) T cells \((i.e., key cells that express the IL-33 receptor, ST2, IL-5 and IL-13 during allergic inflammation)\) and eosinophils, as well as repressing activated B cells both locally and systemically \((Endo et al., 2014; Mato et al., 2017; Wambre et al., 2017)\). Moreover, dupilumab also inhibited HDM-induced expression of CCL26 (eotaxin 3), CCL2 (MCP-1), IL-6 and goblet cell metaplasia responsible for mucus production \((Le Floch et al., 2020)\). Strikingly, treatment of HDM-exposed mice with dupilumab demonstrated an improvement in lung functions (FEV1) \((Gandhi et al., 2016; Gandhi, Pirozzi & Graham, 2017)\).

In clinical trials, dupilumab therapy was able to improve lung functions and reduced levels of Th2-driven inflammatory markers \((e.g., TARC, eotaxin-3, and IgE)\) compared to placebo group in phase II clinical trial of dupilumab in patients with persistent, moderate-to-severe asthma with increased levels of eosinophil \((n = 52)\) \((Wenzel et al., 2013)\). A greater benefit was observed in patients with higher baseline levels of eosinophil in phase III clinical trial (Liberty Asthma QUEST). In the study, moderate-to-severe asthma patients \((n = 1,902)\) were randomly assigned to receive dupilumab (dose of 200 or 300 mg every two weeks) \((n = 631)\) or matched-volume placebos \((n = 317)\) for 52 weeks \((Castro et al., 2018)\). Significantly lower rates of severe asthma exacerbation and improved FEV1 were observed in patients who received dupilumab compared to placebo. Patients with higher baseline
levels of eosinophils exhibited better responses in terms of both exacerbations and the FEV1.

In an accompanying trial, assessment of dupilumab efficacy versus placebo was conducted in a phase III trial (LIBERTY ASTHMA VENTURE) in oral glucocorticoid-dependent severe asthma patients ($n = 210$) (Rabe et al., 2018). Add-on therapy with dupilumab significantly reduced OCS dose used and severe exacerbation rate together with improved FEV1 in the dupilumab group. The first real life cohort study (DUPIN-France) (Dupin et al., 2020) on dupilumab in steroid-dependent severe asthmatic patients ($n = 64$) resulted in improved asthma control, lung functions and reduced oral steroids use. Further improvement in the lung function from these three studies showed a potential effect of dupilumab in airway remodeling. In the most recent phase III clinical trial (TRAVERSE) of dupilumab (Wechsler et al., 2021), the long-term safety and efficacy of dupilumab was assessed in moderate-to-severe or oral corticosteroid-dependent severe asthma ($n = 2,282$). Long-term safety profile in terms of severe asthma exacerbations and lung functions were achieved. The IL-4/IL-13 axis signaling pathway is summarized in Fig. 1. Schematic representation of the cellular effects of IL-4/IL-13

![Figure 1](https://peerj.com/figures/13444/fig-1/full-134444.png)
Figure 2  The potential effects of IL-4 and IL-13 on inflammatory cells and structural changes to epithelial barrier in AR and asthma. Both IL-4 and IL-13 promote B cell class switching to produce IgE, mast cell degranulation to release inflammatory mediators such as histamines, (continued on next page...)
axis in AR and asthma are summarized in Fig. 2. In addition, completed and ongoing clinical trials of anti-IL-4/IL-13 axis mAbs in AR and asthma patients are presented in Table 1.

**CONCLUSION**

Therapies targeting IL-4/IL-13 axis serve as disease-modifying agents that can restore the immune system’s homeostasis. Clinical trials targeting either IL-4 or IL-13 in AR have not yielded beneficial clinical outcomes. Trials involving lebrikizumab and tralokinumab (anti-IL-13 mAb) demonstrated improvements in lung functions but not in asthma symptoms. Hence, targeting both IL-4 and IL-13 has proven to be more successful as exemplified by dupilumab that could reduce inflammatory-driven mediators (e.g., serum IgE, eotaxin-3, TARC and exhaled nitric oxide). However, dupilumab clinical trials do not represent a ‘real world’ asthma with short study duration, and longer duration of dupilumab clinical trials are warranted to assess the long-term safety and tolerability profiles of dupilumab.
| Disease     | Target      | Drug name               | Status of clinical trial | Clinical trials identifier number | Phase | Patient population                                                                 |
|-------------|-------------|-------------------------|--------------------------|-----------------------------------|-------|------------------------------------------------------------------------------------|
| Allergic rhinitis | IL-4        | VAK694                  | Completed                | NCT00929968                       | I     | Atopic subjects with seasonal rhinitis \(n = 35\)                                   |
|             |             |                         |                          | NCT00620230                       | I     | Patients with atopic disease \(n = 46\)                                             |
|             | IL-13       | Dectrekumab             | Completed                | NCT00584584                       | IIA   | Seasonal AR patients \(n = 37\)                                                    |
|             | IL-4Rα      | Dupilumab               | Recruiting/Ongoing       | NCT04502966                       | II    | Moderate to severe seasonal AR and allergic sensitization to grass pollen \(n = 108\) |
| Asthma      | IL-4        | Pascolizumab (SB 240683)| Completed                | NCT00024544                       | I/II  | Symptomatic steroid-naïve subjects with asthma patients \(n = 120\)               |
|             | IL-4Rα      | Altrakincept            | Completed                | N/A (Borish et al., 1999)         | I/II  | Moderate atopic asthma patients \(n = 25\)                                        |
|             | AMG 317     | Completed               | NCT00436670              | II                                 |       | Adult asthma patients \(n = 40\)                                                  |
|             | Pitrakinra  | Completed               | NCT00535028              | II                                 |       | Moderate to severe asthma patients \(n = 294\)                                    |
|             |             |                         | NCT00535031              | II                                 |       | Allergen challenged asthmatic patients \(n = 24\)                                 |
|             |             |                         | NCT00801853              | II                                 |       | A Allergen challenged asthmatic patients \(n = 32\)                               |
|             | Dupilumab   | Completed               | NCT01312961              | II                                 |       | Asthma patients \(n = 424\)                                                       |
|             |             |                         | NCT02528214              | III                                |       | Persistent Moderate to Severe Eosinophilic Asthma                                  |
|             |             |                         | NCT02414854              | III                                |       | Oral glucocorticoid-dependent severe asthma \(n = 210\)                          |
|             |             |                         | NCT04022447              | III                                |       | Moderate-to-severe asthma patients \(n = 1902\)                                   |
|             |             |                         | NCT02134028              | III                                |       | Steroid dependent severe asthmatic patients \(n = 642\)                          |
|             |             |                         |                          | Real-life setting                 |       | Moderate-to-severe or oral corticosteroid (OCS)-dependent severe asthma \(n = 2282\) |
| Disease  | Target       | Drug name                  | Status of clinical trial | Clinical trials identifier number | Phase | Patient population                      |
|----------|--------------|----------------------------|-------------------------|-----------------------------------|-------|----------------------------------------|
| Dupilumab |              | Recruiting/Ongoing         | NCT03694158             | IV                                | Adolescents and adults with asthma ($n = 126$) |
| IL-13    | Cendakimab (RPC4046) | Completed                  | NCT00986037 ($Tripp et al., 2017$) | I   | Mild to moderate controlled asthma patients ($n = 27$) |
|          | Lebrikizumab | Completed                  | NCT01545440 (LUTE) ($Hanania et al., 2015$) | IIb  | Moderate-to-severe asthma patients ($n = 258$) |
|          |              |                           | NCT01545453 (VERSE) ($Hanania et al., 2015$) | IIb  | Moderate-to-severe asthma patients ($n = 205$) |
|          |              |                           | NCT01867125 (LOVALTA I) ($Hanania et al., 2016$) | III  | Uncontrolled asthma patients ($n = 1081$) |
|          |              |                           | NCT01868061 (LAVOLTA II) ($Hanania et al., 2016$) | III  | Uncontrolled asthma patients ($n = 1067$) |
|          | Tralokinumab | Completed                  | NCT00974675 ($Singh et al., 2010$) | I   | Asthma patients ($n = 23$) |
|          |              |                           | NCT01592396 ($Baverel et al., 2015$) | I   | Asthma patients ($n = 23$) |
|          |              |                           | NCT00873860 ($Piper et al., 2013$) | II  | Moderate-to-severe uncontrolled asthma ($n = 194$) |
|          |              |                           | NCT01402986 ($Brightling et al., 2015$) | IIb | Severe uncontrolled asthma patients ($n = 150$) |
|          |              |                           | NCT02449473 (MESOS) ($Russell et al., 2018$) | II  | Moderate-to-severe asthma patients ($n = 39$) |
|          |              |                           | NCT02161757 (STRATOS 1) ($Panettieri Jr et al., 2018$) | III | Severe, uncontrolled asthma ($n = 398$) |
|          |              |                           | NCT02194699 (STRATOS 2) ($Panettieri Jr et al., 2018$) | III | Severe, uncontrolled asthma ($n = 108$) |
|          |              |                           | NCT02281357 (TROPOS) ($Busse et al., 2019$) | III | Severe, uncontrolled asthma patients ($n = 140$) |
|          | IMA-638 and IMA-026 | Completed                | NCT00410280 & NCT00725582 ($Gauvreau et al., 2011$) | I/II | Mild atopic asthma ($n = 56$) |
ADDITIONAL INFORMATION AND DECLARATIONS

Funding
We received funding from the Universiti Sains Malaysia comprising the Research University Grant (1001/PPSP/8012349) awarded to Kah Keng Wong and the Research University Grant (1001.PPSP.8012285) awarded to Noor Suryani Mohd Ashari. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
The Universiti Sains Malaysia comprising the Research University Grant: 1001/PPSP/8012349.
The Research University Grant: 1001.PPSP.8012285.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Siti Muhamad Nur Husna conceived, designed and wrote the manuscript, performed literature search, prepared the figures and tables, revised the manuscript and approved the final draft.
• Norasnieda Md Shukri conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
• Noor Suryani Mohd Ashari conceived and designed the experiments, authored or reviewed drafts of the paper, and approved the final draft.
• Kah Keng Wong conceived, designed and wrote the manuscript, performed literature search, revised the manuscript, and approved the final draft.

Data Availability
The following information was supplied regarding data availability:
This is a review article.

REFERENCES

Azid NA, Sani MM, Zamry AA, Ashari NSM, Tan TH-T, Wong KK, Mohamud R. 2019. Total IgE levels and their relevance in the diagnosis of allergy among Malaysian population in the North-East Region of Peninsular Malaysia. Journal of Biomedical and Clinical Sciences 4:1–7.

Bartolome RA, Jaen M, Casal JJ. 2018. An IL13Ralpha2 peptide exhibits therapeutic activity against metastatic colorectal cancer. British Journal of Cancer 119:940–949 DOI 10.1038/s41416-018-0259-7.
Baverel PG, Jain M, Stelmach I, She D, Agoram B, Sandbach S, Piper E, Kuna P. 2015. Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing. British Journal of Clinical Pharmacology 80:1337–1349 DOI 10.1111/bcp.12725.

Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttmann-Yassky E, Suarez-Farinas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR. 2014. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. New England Journal of Medicine 371:130–139 DOI 10.1056/NEJMoa1314768.

Belsky DW, Sears MR, Hancox RJ, Harrington H, Houts R, Moffitt TE, Sugden K, Williams B, Poulton R, Caspi A. 2013. Polygenic risk and the development and course of asthma: an analysis of data from a four-decade longitudinal study. The Lancet Respiratory Medicine 1:453–461 DOI 10.1016/S2213-2600(13)70101-2.

Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME. 2005. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clinical and Experimental Allergy 35:1096–1103 DOI 10.1111/j.1365-2222.2005.02299.x.

Blauvelt A, De Bruin Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prems E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemeny I, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. 2017. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. The Lancet 389:2287–2303 DOI 10.1016/S0140-6736(17)31191-1.

Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM, Group I-RAS. 2001. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. Journal of Allergy and Clinical Immunology 107:963–970 DOI 10.1067/mai.2001.115624.

Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L. 1999. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine 160:1816–1823 DOI 10.1164/ajrccm.160.6.9808146.

Bourdin A, Papi AA, Corren J, Virchow JC, Rice MS, Deniz Y, Djandji M, Rowe P, Pavord ID. 2021. Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. 76:269–280.

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, Van Weel C, Agache I, Ait-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douaghi H, Durham SR, Van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O’Hehir RE,
Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, Van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D, World Health O, Galen, Allergen. 2008. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and Allergen). Allergy 63(Suppl 86):S8–S160 DOI 10.1111/j.1398-9995.2007.01620.x.

Bousquet J, Van Cauwenberge P, Khaltaev N, Aria Workshop G, World Health O. 2001. Allergic rhinitis and its impact on asthma. Journal of Allergy and Clinical Immunology 108:S147–S334 DOI 10.1067/mai.2001.118891.

Brightling CE, Chanez P, Leigh R, O’Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E. 2015. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet Respiratory Medicine 3:692–701 DOI 10.1016/S2213-2600(15)00197-6.

Busse WW, Brusselle GG, Korn S, Kuna P, Magnan A, Cohen D, Bowen K, Piechowiak T, Wang MM, Colice G. 2019. Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. European Respiratory Journal 53:1800948 DOI 10.1183/13993003.00948-2018.

Capaldo CT, Nusrat A. 2009. Cytokine regulation of tight junctions. Biochimica et Biophysica Acta/General Subjects 1788:864–871 DOI 10.1016/j.bbamem.2008.08.027.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford I, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martinova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. 2018. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. New England Journal of Medicine 378:2486–2496 DOI 10.1056/NEJMoa1804092.

Chaker AM, Shamji MH, Dumitru FA, Calderon MA, Scadding GW, Makatsori M, Jones I, He QA, Subramanian KK, Arm JP, Durham SR, Schmidt-Weber CB. 2016. Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: a randomized controlled trial. Journal of Allergy and Clinical Immunology 137:452–461 e459 DOI 10.1016/j.jaci.2015.08.046.

Conde E, Bertrand R, Balbino B, Bonnefoy J, Stackowicz J, Caillot N, Colaone F, Hamdi S, Houmadi R, Loste A, Kamphuis BJB, Huetz F, Guilleminault L, Gaudenzi N, Mougel A, Hardy D, Snouwaert JN, Koller BH, Serra V, Bruhns P, Grouard-Vogel G, Reber LL. 2021. Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice. Nature Communications 12:2574 DOI 10.1038/s41467-021-22834-5.
Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, Wenzel SE, Chon Y, Dunn M, Weng HH, Lin SL. 2010. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. *American Journal of Respiratory and Critical Care Medicine* **181**:788–796 DOI 10.1164/rccm.200909-1448OC.

Corren J, Lemanske Jr RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z. 2011. Lebrikizumab treatment in adults with asthma. *New England Journal of Medicine* **365**:1088–1098 DOI 10.1056/NEJMoa1106469.

Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, De Blay F, Bonniaud P, Leroyer C, Mahay G, Girodet PO, Raherison C, Fry S, Bourdelles GL, Proust A, Rosencher L, Garcia G, Bourdin A, Chenivesse C, Didier A, Couffignal C, Taille C. 2020. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. *Clinical and Experimental Allergy* **50**:789–798 DOI 10.1111/cea.13614.

Eguiluz-Gracia I, Mathioudakis AG, Bartel S, Vijverberg SJH, Fuertes E, Comberiati P, Cai YS, Tomacic PV, Diamant Z, Vestbo J, Galan C, Hoffmann B. 2020. The need for clean air: the way air pollution and climate change affect allergic rhinitis and asthma. *Allergy* **75**:2170–2184 DOI 10.1111/all.14177.

Endo Y, Hirahara K, Yagi R, Tumes DJ, Nakayama T. 2014. Pathogenic memory type Th2 cells in allergic inflammation. *Trends in Immunology* **35**:69–78 DOI 10.1016/j.it.2013.11.003.

Enilari O, Sinha S. 2019. The global impact of asthma in adult populations. *Annals of Global Health* **85** DOI 10.5334/aogh.2412.

Ferreira MA, Vonk JM, Baurecht H, Marenholz I, Tian C, Hoffman JD, Helmer Q, Tillander A, Uleman V, Van Dongen J, Lu Y, Ruschendorf F, Esparza-Gordillo J, Medway CW, Mountjoy E, Burrows K, Hummel O, Grosche S, Brumpton BM, Witte JS, Hottenga JJ, Willemsen G, Zheng J, Rodriguez E, Hotze M, Franke A, Revez JA, Beesley J, Matheson MC, Dharmage SC, Bain LM, Fritsche LG, Gabrielsen ME, Balliu B, andMe Research T, collaborators A, consortium B, Life Lines Cohort S, Nielsen JB, Zhou W, Hveem K, Langhammer A, Holmen OL, Loset M, Abecasis GR, Willer CJ, Arnold A, Homuth G, Schmidt CO, Thompson PJ, Martin NG, Duffy DL, Novak N, Schulz H, Karrasch S, Gieger C, Strauch K, Melles RB, Hinds DA, Hubner N, Weidinger S, Magnusson PKE, Jansen R, Jorgenson E, Lee YA, Boomsma DI, Almqvist C, Karlsson R, Koppelman GH, Paternoster L. 2017. Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. *Nature Genetics* **49**:1752–1757 DOI 10.1038/ng.3985.

Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. 2006. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. *Nature Medicine* **12**:99–106 DOI 10.1038/nm1332.

Le Floc’h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, Bai Y, Lim WK, Martin J, Huang T, Potocky TB, Kim JH, Rafique A, Papadopoulos NJ, Stahl N,
Yancopoulos GD, Murphy AJ, Sleeman MA, Orengo JM. 2020. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. *Allergy* 75:1188–1204 DOI 10.1111/all.14151.

Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. 2016. Targeting key proximal drivers of type 2 inflammation in disease. *Nature Reviews Drug Discovery* 15:35–50 DOI 10.1038/nrd4624.

Gandhi NA, Pirozzi G, Graham NMH. 2017. Commonality of the IL-4/IL-13 pathway in atopic diseases. *Expert Review of Clinical Immunology* 13:425–437 DOI 10.1080/1744666X.2017.1298443.

Gauvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RM, Y N, Zhou S, Raible D, O’Byrne PM. 2011. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. *American Journal of Respiratory and Critical Care Medicine* 183:1007–1014 DOI 10.1164/rccm.201008-1210OC.

Giuffrida P, Caprioli F, Facciotti F, Di Sabatino A. 2019. The role of interleukin-13 in chronic inflammatory intestinal disorders. *Autoimmunity Reviews* 18:549–555 DOI 10.1016/j.autrev.2019.03.012.

Gruber R, Bornchen C, Rose K, Daubmann A, Volksdorf T, Władykowski E, Vidal YSS, Peters EM, Danso M, Bouwstra JA, Hennies HC, Moll I, Schmuth M, Brandner JM. 2015. Diverse regulation of claudin-1 and claudin-4 in atopic dermatitis. *American Journal of Pathology* 185:2777–2789 DOI 10.1016/j.ajpath.2015.06.021.

Hamilton JD, Suarez-Farinas M, Dhingra N, Cardinale I, Li X, Kostic A, Ming JE, Radin AR, Krueger JG, Graham N, Yancopoulos GD, Pirozzi G, Guttman-Yassky E. 2014. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. *Journal of Allergy and Clinical Immunology* 134:1293–1300 DOI 10.1016/j.jaci.2014.10.013.

Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG. 2016. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. *The Lancet Respiratory Medicine* 4:781–796 DOI 10.1016/S2213-2600(16)30265-X.

Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, Cheu M, Putnam WS, Murray E, Scheerens H, Holweg CT, Maciuca R, Gray S, Doyle R, McClintock D, Olsson J, Matthews JG, Yen K. 2015. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. *Thorax* 70:748–756 DOI 10.1136/thoraxjnl-2014-206719.

Harb H, Chatila TA. 2020. Mechanisms of Dupilumab. *Clinical & Experimental Allergy* 50:5–14 DOI 10.1111/cea.13491.

Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM. 2002. Preclinical efficacy and safety of pascolizumab (SB 240683): a
humanized anti-interleukin-4 antibody with therapeutic potential in asthma. *Clinical and Experimental Immunology* **130**:93–100 DOI 10.1046/j.1365-2249.2002.01973.x.

Heijink IH, Nawijn MC, Hackett TL. 2014. Airway epithelial barrier function regulates the pathogenesis of allergic asthma. *Clinical and Experimental Allergy* **44**:620–630 DOI 10.1111/cea.12296.

Holgate ST. 2007. Epithelium dysfunction in asthma. *Journal of Allergy and Clinical Immunology* **120**:1233–1244 DOI 10.1016/j.jaci.2007.10.025.

Hoppenot D, Malakauskas K, Lavinskiene S, Sakalauskas R. 2015. p-STAT6, PU.1, and NF-κB are involved in allergen-induced late-phase airway inflammation in asthma patients. 15:1–11.

Ito T, Suzuki S, Kanaji S, Shiraishi H, Ohta S, Arima K, Tanaka G, Tamada T, Honjo E, Garcia KC, Kuroki R, Izuhara K. 2009. Distinct structural requirements for interleukin-4 (IL-4) and IL-13 binding to the shared IL-13 receptor facilitate cellular tuning of cytokine responsiveness. *Journal of Biological Chemistry* **284**:24289–24296 DOI 10.1074/jbc.M109.007286.

Iwaszko M, Biały S, Bogunia-Kubik K. 2021. Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. *Cells* **10**:3000 DOI 10.3390/cells10113000.

Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK. 2006. Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases. *Vitamins and Hormones* **74**:479–504 DOI 10.1016/S0083-6729(06)74019-5.

Kariyawasam H, Nicholson G, Tan A, Syngal N, Quinn D, Boulton C, Walker C, Rodman D, Westwick J, Kon OM. 2009. Effects of Anti-IL-13 (Novartis QAX576) on inflammatory responses following nasal allergen challenge (NAC). *American Journal of Respiratory and Critical Care Medicine* **179**:A3642 DOI 10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A3642.

Koller FL, Hwang DG, Dozier EA, Fingleton B. 2010. Epithelial interleukin-4 receptor expression promotes colon tumor growth. *Carcinogenesis* **31**:1010–1017 DOI 10.1093/carcin/bgq044.

London Jr NR, Tharakan A, Ramanathan Jr M. 2016. The role of innate immunity and aeroallergens in chronic rhinosinusitis. *Advances in Oto-Rhino-Laryngology* **79**:69–77 DOI 10.1159/000445132.

Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymiou WT, Yasenchak J, Frednewey D, Valenzuela DM, Giallourakis CC, Alt FW, Yancopoulos GD, Murphy AJ. 2014. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. *Proceedings of the National Academy of Sciences of the United States of America* **111**:5147–5152 DOI 10.1073/pnas.1323896111.

Malaviya R, Laskin DL, Malaviya RJ. 2010. Janus kinase-3 dependent inflammatory responses in allergic asthma. *International Immunopharmacology* **10**:829–836 DOI 10.1016/j.intimp.2010.04.014.

Mato N, Hirahara K, Ichikawa T, Kumagai J, Nakayama M, Yamasawa H, Bando M, Hagiwara K, Sugiyama Y, Nakayama T. 2017. Memory-type ST2(+)CD4(+) T cells participate in the steroid-resistant pathology of eosinophilic pneumonia. *Scientific Reports* **7**:6805 DOI 10.1038/s41598-017-06962-x.
May R, Fung M. 2015. Strategies targeting the IL-4/IL-13 axes in disease. [cited 2017 Jul 24]. Cytokine 75(1):89–116 DOI 10.1016/j.cyto.2015.05.018.

Meng Y, Wang C, Zhang L. 2020. Advances and novel developments in allergic rhinitis. Allergy 75:3069–3076 DOI 10.1111/all.14586.

Meurs H, Zaagsma J, Maarsingh H, Van Duin MJA. 2019. Recent patents in allergy/immunology: use of arginine inhibitors in the treatment of asthma and allergic rhinitis. 74:1206.

Network GAJA, New Zealand. 2014. The global asthma report 2014. 769. 28–36.

Nguyen JK, Austin E, Huang A, Mamalis A, Jagdeo J. 2020. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Archives of Dermatological Research 312:81–92 DOI 10.1007/s00403-019-01972-3.

Nicholson GC, Kariyawasam HH, Tan AJ, Hohlfeld JM, Quin D, Walker C, Rodman D, Westwick J, Jurcevic S, Kon OM, Barnes PJ, Krug N, Hansel TT. 2011. The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. Journal of Allergy and Clinical Immunology 128:800–807 e809 DOI 10.1016/j.jaci.2011.05.013.

Nur Husna SM, Md Shukri N, Tan H-TT, Mohd Ashari NS, Wong KK. 2022a. Higher wheal sizes of Dermatophagoides farinae sensitization exhibit worse nasal symptoms in allergic rhinitis patients. Frontiers in Medicine 9:843432 DOI 10.3389/fmed.2022.843432.

Nur Husna SM, Shukri N, Tuan Sharif SE, Tan HTT, Mohd Ashari NS, Wong KK. 2022b. IL-4–IL-13 axis in allergic rhinitis: elevated serum cytokine levels and inverse association with tight junction molecules expression. Frontiers in Molecular Biosciences 9:819772 DOI 10.3389/fmolb.2022.819772.

Nur Husna SM, Siti Sarah CO, Tan HT, Md Shukri N, Mohd Ashari NS, Wong KK. 2021a. Reduced occludin and claudin-7 expression is associated with urban locations and exposure to second-hand smoke in allergic rhinitis patients. Scientific Reports 11:1245 DOI 10.1038/s41598-020-79208-y.

Nur Husna SM, Tan HT, Md Shukri N, Mohd Ashari NS, Wong KK. 2021b. Nasal epithelial barrier integrity and tight junctions disruption in allergic rhinitis: overview and pathogenic insights. Frontiers in Immunology 12:663626 DOI 10.3389/fimmu.2021.663626.

Ober C, Yao TC. 2011. The genetics of asthma and allergic disease: a 21st century perspective. Immunological Reviews 242:10–30 DOI 10.1111/j.1600-065X.2011.01029.x.

O’Dwyer DN, Moore BB. 2017. The role of periostin in lung fibrosis and airway remodeling. Cellular and Molecular Life Science 74:4305–4314 DOI 10.1007/s00018-017-2649-z.

Panettieri Jr RA, Sjobring U, Peterfy A, Wessman P, Bowen K, Piper E, Colice G, Brightling CE. 2018. Tralokinumab for severe, uncontrolled asthma
(STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. *The Lancet Respiratory Medicine* 6:511–525 DOI 10.1016/S2213-2600(18)30184-X.

Paul WE. 2015. History of interleukin-4. *Cytokine* 75:3–7 DOI 10.1016/j.cyto.2015.01.038.

Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, She D, Kell C, May RD, Geba GP, Molfino NA. 2013. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. *European Respiratory Journal* 41:330–338 DOI 10.1183/09031936.00223411.

Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LM, Kemp B, Spooner J, Keen J, Minter R, Uddin F, Colice G, Wilkinson T, Vaughan T, May RD. 2017. Structural characterisation reveals mechanism of IL-13-Neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2. *Journal of Molecular Biology* 429:208–219 DOI 10.1016/j.jmb.2016.12.005.

Ptackova P, Musil J, Stach M, Lesny P, Nemeckova S, Kral V, Fabry M, Otahal P. 2018. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21. *Cytotherapy* 20:507–520 DOI 10.1016/j.jcyt.2017.10.001.

Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Stauringer H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A. 2018. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. *New England Journal of Medicine* 378:2475–2485 DOI 10.1056/NEJMoa1804093.

Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A, Jones I, Arm JP, Strieter RM, Sabo R, Gunawardena KA. 2015. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. *Journal of Allergy and Clinical Immunology* 135:500–507 DOI 10.1016/j.jaci.2014.07.049.

Russell RJ, Chachi L, FitzGerald JM, Backer V, Olivenstein R, Titlestad IL, Ulrik CS, Harrison T, Singh D, Chaudhuri R, Leaker B, McGarvey L, Siddiqui S, Wang M, Braddock M, Nordenmark LH, Cohen D, Parikh H, Colice G, Brightling CE, investigators Ms. 2018. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. *The Lancet Respiratory Medicine* 6:499–510 DOI 10.1016/S2213-2600(18)30201-7.

Russkamp D, Aguilar-Pimentel A, Alessandrini F, Gailus-Durner V, Fuchs H, Ohnmacht C, Chaker A, De Angelis MH, Ollert M, Schmidt-Weber CB, Blank S. 2019. IL-4 receptor alpha blockade prevents sensitization and alters acute and long-lasting effects of allergen-specific immunotherapy of murine allergic asthma. *Allergy* 74:1549–1560 DOI 10.1111/all.13759.

Sahoo A, Wali S, Nurieva R. 2016. T helper 2 and T follicular helper cells: regulation and function of interleukin-4. *Cytokine and Growth Factor Reviews* 30:29–37 DOI 10.1016/j.cytogfr.2016.03.011.
Sani MM, Ashari NSM, Abdullah B, Wong KK, Musa KI, Mohamud R, Tan HT. 2019. Reduced CD4+ terminally differentiated effector memory T cells in moderate-severe house dust mites sensitized allergic rhinitis patients. *Asian Pacific Journal of Allergy and Immunology* 37:138–146 DOI 10.12932/AP-191217-0220.

Shames R, Vexler V, Lane N, McClellan M, Shi J, Keller S, Young D, Nieman R, Hart TK. 2001. The safety and pharmacokinetics of SB240683 in patients with mild to moderate asthma. *Journal of Allergy and Clinical Immunology* 107:S316.

Simpson EL, Bieber T, Guttmann-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M, Solo, Investigators S. 2016. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *New England Journal of Medicine* 375:2335–2348 DOI 10.1056/NEJMoa1610020.

Sin B, Togias A. 2011. Pathophysiology of allergic and nonallergic rhinitis. *Proc Am Thorac Soc* 8:106–114 DOI 10.1513/pats.201008-057RN.

Singh D, Kane B, Molino NA, Faggioni R, Roskos L, Woodcock A. 2010. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. *BMC Pulmonary Medicine* 10:3 DOI 10.1186/1471-2466-10-3.

Sinyor B, Perez LC. 2020. Pathophysiology of Asthma. Treasure Island (FL): StatPearls.

Siti Sarah CO, Md Shukri N, Mohd Ashari NS, Wong KK. 2020. Zonula occludens and nasal epithelial barrier integrity in allergic rhinitis. *PeerJ* 8:e9834 DOI 10.7717/peerj.9834.

Skoner DP. 2001. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. *Journal of Allergy and Clinical Immunology* 108:S2–S8 DOI 10.1067/mai.2001.115569.

Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE, Meyers DA, Bleecker ER. 2012. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. *Journal of Allergy and Clinical Immunology* 130:516–522 DOI 10.1016/j.jaci.2012.03.030.

Steelant B, Farre R, Wawrzyniak P, Belmans J, Dekimpe E, Vanheel H, Van Gerven L, Kortekaas Krohn I, Bullens DMA, Ceuppens JL, Akdis CA, Boeckxstaens G, Seys SF, Hellings PW. 2016a. Impaired barrier function in patients with house dust mite-induced allergic rhinitis is accompanied by decreased occludin and zonula occludens-1 expression. *Journal of Allergy and Clinical Immunology* 137:1043–1053 e1045 DOI 10.1016/j.jaci.2015.10.050.

Steelant B, Seys SF, Boeckxstaens G, Akdis CA, Ceuppens JL, Hellings PW. 2016b. Restoring airway epithelial barrier dysfunction: a new therapeutic challenge in allergic airway disease. *Rhinology* 54:195–205 DOI 10.4193/Rhin15.376.

Steelant B, Seys SF, Van Gerven L, Van Woensel M, Farre R, Wawrzyniak P, Kortekaas Krohn I, Bullens DM, Talavera K, Raap U, Boon L, Akdis CA, Boeckxstaens G, Ceuppens JL, Hellings PW. 2018. Histamine and T helper cytokine-driven epithelial
barrier dysfunction in allergic rhinitis. *Journal of Allergy and Clinical Immunology* **141**:951–963 DOI 10.1016/j.jaci.2017.08.039.

Stone KD, Prussin C, Metcalfe DD. 2010. IgE, mast cells, basophils, and eosinophils. *Journal of Allergy and Clinical Immunology* **125**:S73–S80 DOI 10.1016/j.jaci.2009.11.017.

Tan HT, Sugita K, Akdis CA. 2016. Novel biologicals for the treatment of allergic diseases and asthma. *Current Allergy and Asthma Reports* **16**:70 DOI 10.1007/s11882-016-0650-5.

Thaci D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NM, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. 2016. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. *Lancet* **387**:40–52 DOI 10.1016/S0140-6736(15)00388-8.

Togias A. 2003. Rhinitis and asthma: evidence for respiratory system integration. *Journal of Allergy and Clinical Immunology* **111**:1171–1183 quiz 1184 DOI 10.1067/mai.2003.1592.

Tripp CS, Cuff C, Campbell AL, Hendrickson BA, Voss J, Melim T, Wu C, Cherniack AD, Kim K. 2017. RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 alpha1 and alpha2 receptors: a randomized, double-blind, placebo-controlled, dose-escalation first-in-human study. *Advances in Therapy* **34**:1364–1381 DOI 10.1007/s12325-017-0525-8.

Van Beijsterveldt CE, Boomsma DI. 2007. Genetics of parentally reported asthma, eczema and rhinitis in 5-yr-old twins. *European Respiratory Journal* **29**:516–521 DOI 10.1183/09031936.00065706.

Van Den Berg MP, Meurs H, Gosens R. 2018. Targeting arginase and nitric oxide metabolism in chronic airway diseases and their co-morbidities. *Current Opinion in Pharmacology* **40**:126–133 DOI 10.1016/j.coph.2018.04.010.

Wambre E, Bajzik V, De Long JH, O’Brien K, Nguyen QA, Speake C, Gersuk VH, De Berg HA, Whalen E, Ni C, Farrington M, Jeong D, Robinson D, Linsley PS, Vickery BP, Kwok WW. 2017. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. *Science Translational Medicine* **9**:eaam9171 DOI 10.1126/scitranslmed.aam9171.

Wang Ms J, Kang Ms X, Huang Ms ZQ, Shen Ms L, Luo Md Q, Li Ms MY, Luo Ms LP, Tu Ms JH, Han Ms M, Ye J. 2021. Protease-Activated Receptor-2 Decreased Zonula Occludens-1 and Claudin-1 expression and induced epithelial barrier dysfunction in allergic rhinitis. *American Journal of Rhinology & Allergy* **35**:26–35 DOI 10.1177/1945892420932486.

Wang X, Xu C, Ji J, Cai Y, Shu Y, Chao Y, Wu X, Zou C, Wu X, Tang L. 2020. IL-4/IL-13 upregulates Sonic hedgehog expression to induce allergic airway epithelial remodeling. *The American Journal of Physiology–Lung Cellular and Molecular Physiology* **318**:L888–L899 DOI 10.1152/ajplung.00186.2019.
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. 2021. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVE-VERSE): an open-label extension study. The Lancet Respiratory Medicine 10:11–25 DOI 10.1016/S2213-2600(21)00322-2.

Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G. 2013. Dupilumab in persistent asthma with elevated eosinophil levels. New England Journal of Medicine 368:2455–2466 DOI 10.1056/NEJMoa1304048.

Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. 2007. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370:1422–1431 DOI 10.1016/S0140-6736(07)61600-6.

Wills-Karp M, Finkelman FD. 2008. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Science Signaling 1:pe55 DOI 10.1126/scisignal.1.51.pe55.

Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. 2009. T-helper type 2-driven inflammation defines major subphenotypes of asthma. American Journal of Respiratory and Critical Care Medicine 180:388–395 DOI 10.1164/rccm.200903-0392OC.

Yamanishi Y, Miyake K, Iki M, Tsutsui H, Karasuyama H. 2017. Recent advances in understanding basophil-mediated Th2 immune responses. Immunological Reviews 278:237–245 DOI 10.1111/imr.12548.

Yang G, Volk A, Petley T, Emmell E, Giles–Komar J, Shang X, Li J, Das AM, Shealy D, Griswold DE, Li L. 2004. Anti–IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine 28:224–232 DOI 10.1016/j.cyto.2004.08.007.

Yip W, Hughes MR, Li Y, Cai A, Hirst M, Mohn WW, McNagny KM. 2021. Butyrate shapes immune cell fate and function in allergic asthma. Frontiers in Immunology 12:628453 DOI 10.3389/fimmu.2021.628453.

Yu S, Jin L, Che N, Zhang R, Xu F, Han B. 2019. Dendritic cells modified with Der p1 antigen as a therapeutic potential for allergic rhinitis in a murine model via regulatory effects on IL-4, IL-10 and IL-13. International Immunopharmacology 70:216–224 DOI 10.1016/j.intimp.2019.02.045.